297 related articles for article (PubMed ID: 23818224)
1. Tubulin-interactive stilbene derivatives as anticancer agents.
Mikstacka R; Stefański T; Różański J
Cell Mol Biol Lett; 2013 Sep; 18(3):368-97. PubMed ID: 23818224
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.
Cushman M; Nagarathnam D; Gopal D; Chakraborti AK; Lin CM; Hamel E
J Med Chem; 1991 Aug; 34(8):2579-88. PubMed ID: 1875350
[TBL] [Abstract][Full Text] [Related]
3. Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin a-4.
Marrelli M; Conforti F; Statti GA; Cachet X; Michel S; Tillequin F; Menichini F
Curr Med Chem; 2011; 18(20):3035-81. PubMed ID: 21651481
[TBL] [Abstract][Full Text] [Related]
4. Combretastatins: In vitro structure-activity relationship, mode of action and current clinical status.
Jaroch K; Karolak M; Górski P; Jaroch A; Krajewski A; Ilnicka A; Sloderbach A; Stefański T; Sobiak S
Pharmacol Rep; 2016 Dec; 68(6):1266-1275. PubMed ID: 27686966
[TBL] [Abstract][Full Text] [Related]
5. Interaction of 4-arylcoumarin analogues of combretastatins with microtubule network of HBL100 cells and binding to tubulin.
Rappl C; Barbier P; Bourgarel-Rey V; Grégoire C; Gilli R; Carre M; Combes S; Finet JP; Peyrot V
Biochemistry; 2006 Aug; 45(30):9210-8. PubMed ID: 16866367
[TBL] [Abstract][Full Text] [Related]
6. Development of novel derivatives of stilbene and macrocyclic compounds as potent of anti-microtubule factors.
Borys F; Tobiasz P; Poterała M; Krawczyk H
Biomed Pharmacother; 2021 Jan; 133():110973. PubMed ID: 33378993
[TBL] [Abstract][Full Text] [Related]
7. Stilbene derivatives that are colchicine-site microtubule inhibitors have antileukemic activity and minimal systemic toxicity.
Cao TM; Durrant D; Tripathi A; Liu J; Tsai S; Kellogg GE; Simoni D; Lee RM
Am J Hematol; 2008 May; 83(5):390-7. PubMed ID: 18175355
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic Stilbenes and Derivatives as Promising Antimitotic Leads for Cancer Therapy.
Faustino C; Francisco AP; Isca VMS; Duarte N
Curr Pharm Des; 2018; 24(36):4270-4311. PubMed ID: 30636588
[TBL] [Abstract][Full Text] [Related]
9. The interaction with tubulin of a series of stilbenes based on combretastatin A-4.
Woods JA; Hadfield JA; Pettit GR; Fox BW; McGown AT
Br J Cancer; 1995 Apr; 71(4):705-11. PubMed ID: 7710932
[TBL] [Abstract][Full Text] [Related]
10. 4,5-Diaryl-3-aminopyrazole derivatives as analogs of Combretastatin A-4: synthesis and biological evaluation.
Liu T; Cui R; Chen J; Zhang J; He Q; Yang B; Hu Y
Arch Pharm (Weinheim); 2011 May; 344(5):279-86. PubMed ID: 21290430
[TBL] [Abstract][Full Text] [Related]
11. Thiazolidinone Constraint Combretastatin Analogs as Novel Antitubulin Agents: Design, Synthesis, Biological Evaluation and Docking Studies.
Sharma S; Gupta MK; Saxena AK; Bedi PM
Anticancer Agents Med Chem; 2017; 17(2):230-240. PubMed ID: 27141882
[TBL] [Abstract][Full Text] [Related]
12. Systematic Studies on Anti-Cancer Evaluation of Stilbene and Dibenzo[
Borys F; Tobiasz P; Poterała M; Fabczak H; Krawczyk H; Joachimiak E
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110792
[TBL] [Abstract][Full Text] [Related]
13. Combretastatin-based compounds with therapeutic characteristics: a patent review.
Nainwal LM; Alam MM; Shaquiquzzaman M; Marella A; Kamal A
Expert Opin Ther Pat; 2019 Sep; 29(9):703-731. PubMed ID: 31369715
[No Abstract] [Full Text] [Related]
14. Exploring Diverse-Ring Analogues on Combretastatin A4 (CA-4) Olefin as Microtubule-Targeting Agents.
Song MY; He QR; Wang YL; Wang HR; Jiang TC; Tang JJ; Gao JM
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32155790
[TBL] [Abstract][Full Text] [Related]
15. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study.
Lin CM; Singh SB; Chu PS; Dempcy RO; Schmidt JM; Pettit GR; Hamel E
Mol Pharmacol; 1988 Aug; 34(2):200-8. PubMed ID: 3412321
[TBL] [Abstract][Full Text] [Related]
16. Quantum chemistry calculation-aided structural optimization of combretastatin A-4-like tubulin polymerization inhibitors: improved stability and biological activity.
Jiang J; Zheng C; Zhu K; Liu J; Sun N; Wang C; Jiang H; Zhu J; Luo C; Zhou Y
J Med Chem; 2015 Mar; 58(5):2538-46. PubMed ID: 25689111
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Anti-cancer Activity of Stilbene and Methoxydibenzo[b,f] oxepin Derivatives.
Garbicz D; Mielecki D; Wrzesinski M; Pilzys T; Marcinkowski M; Piwowarski J; Debski J; Palak E; Szczecinski P; Krawczyk H; Grzesiuk E
Curr Cancer Drug Targets; 2018; 18(7):706-717. PubMed ID: 28669347
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of novel combretastatin A-4 thio derivatives as microtubule targeting agents.
Stefański T; Mikstacka R; Kurczab R; Dutkiewicz Z; Kucińska M; Murias M; Zielińska-Przyjemska M; Cichocki M; Teubert A; Kaczmarek M; Hogendorf A; Sobiak S
Eur J Med Chem; 2018 Jan; 144():797-816. PubMed ID: 29291446
[TBL] [Abstract][Full Text] [Related]
19. Combretastatin A-4 analogues as antimitotic antitumor agents.
Nam NH
Curr Med Chem; 2003 Sep; 10(17):1697-722. PubMed ID: 12871118
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and Evaluation of 2-Naphthaleno trans-Stilbenes and Cyanostilbenes as Anticancer Agents.
Madadi NR; Penthala NR; Ketkar A; Eoff RL; Trujullo-Alonso V; Guzman ML; Crooks PA
Anticancer Agents Med Chem; 2018; 18(4):556-564. PubMed ID: 28403783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
